Brought to you by 
Gilead acquires Triangle for $464mm
20 Dec 2002
Executive Summary
Anti-infective therapeutics company Gilead Sciences is acquiring fellow antiviral drug developer Triangle Pharmaceuticals in a $464mm cash deal. It pays $6 per share, about a 42% premium to the market average price.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead acquires Triangle for $464mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice